2025
Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stagesDeterminants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerEndocrine therapyImmune infiltrationPrediction of pCRAnti-HER2 therapyLuminal A phenotypeHigher immune infiltrationFemale breast cancerHER2 blockadeDeterminants of responseTumor responseInfiltrating lymphocytesCDK4/6 inhibitionAnti-HER2HER2 targetingClinical endpointsER signalingKi67Response groupCancerTherapyTherapeutic targetMolecular changesTumorOATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor-Associated Arthralgia Susceptibility.
Taheri H, Li Y, Huang K, Ahmed E, Jin Y, Drabison T, Yang Y, Kulp S, Young N, Li J, Cheng X, Corps K, Coss C, Vaughn J, Lustberg M, Sparreboom A, Hu S. OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor-Associated Arthralgia Susceptibility. Cancer Research Communications 2025, 5: 496-510. PMID: 40062557, PMCID: PMC11948302, DOI: 10.1158/2767-9764.crc-24-0475.Peer-Reviewed Original ResearchMeSH KeywordsAromatase InhibitorsArthralgiaBreast NeoplasmsFemaleHumansLiver-Specific Organic Anion Transporter 1An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Schrank B, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin A, Jeong S, Antony A, Chang M, Kang M, Gallup T, Koong A, Li J, Yun K, Kim B, Jiang W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 2025, 6: 511-527. PMID: 40000910, DOI: 10.1038/s43018-025-00919-0.Peer-Reviewed Original ResearchConceptsAntibody-toxin conjugatesTumor cellsImmune recognition of tumor cellsEnhanced antigen cross-presentationRecognition of tumor cellsCancer cell phagocytosisTumor-derived antigensToxin listeriolysin OTumor-derived peptidesImproved animal survivalPromote immune recognitionCytosolic immune sensorsIntracellular bacterium Listeria monocytogenesTreatment in vivoTreating multiple cancersPhagocytosis checkpointsCheckpoint blockadeCancer immunotherapySignal CD47Listeriolysin OMetastatic breastMelanoma tumorsTherapeutic strategiesAnimal survivalCell phagocytosisRacial and ethnic disparities in conversion to mastectomy following lumpectomy
Khubchandani J, KC M, Dey P, Proussaloglou E, Valero M, Berger E, Park T, Gross C, Butler P, Fayanju O, Winer E, Golshan M, Greenup R. Racial and ethnic disparities in conversion to mastectomy following lumpectomy. Breast Cancer Research And Treatment 2025, 211: 99-110. PMID: 39937397, DOI: 10.1007/s10549-025-07625-6.Peer-Reviewed Original ResearchConceptsConversion to mastectomyNeoadjuvant chemotherapyBreast conservationStage 0-III breast cancerWhite womenBreast cancerBlack womenBreast cancer careNational Cancer DatabaseMultivariate logistic regression modelEvaluate contemporary trendsLogistic regression modelsCancer careImprove disparitiesEthnic disparitiesDiagnosis yearInitial lumpectomySocio-demographicCancer DatabaseClinical factorsMastectomyLumpectomySurgeryResultsThe studyTreatment sequenceSurgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsDisease ManagementFemaleHepatectomyHumansLiver NeoplasmsTreatment OutcomeConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgeryParadoxical control of multifocal mammary oncogenesis by radiation therapy
Galluzzi L, Buqué A. Paradoxical control of multifocal mammary oncogenesis by radiation therapy. OncoImmunology 2025, 14: 2458886. PMID: 39873285, PMCID: PMC11776481, DOI: 10.1080/2162402x.2025.2458886.Peer-Reviewed Original ResearchClinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-targeted therapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapyAdjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer
Filho O, Ballman K, Campbell J, Liu M, Ligibel J, Watson M, Chen E, Du L, Stover D, Carey L, Partridge A, Kirshner J, Muss H, Hudis C, Winer E, Norton L, Symmans W. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal Of Clinical Oncology 2025, 43: 1229-1239. PMID: 39746162, DOI: 10.1200/jco-24-01875.Peer-Reviewed Original ResearchConceptsDose-dense chemotherapyDisease-free survivalOverall survivalBreast cancerTumor burdenMenopausal statusLong-term disease-free survivalHormone receptor-positive breast cancerHazard ratioNode-positive breast cancerSensitivity to endocrine therapyReceptor-positive breast cancerDose-dense therapyER-negative subsetEstrogen receptor-positiveER+ breast cancerMolecular subtype classificationSustained long-term benefitsER+ cancersDose-denseER statusReceptor-positiveEndocrine therapyConventional chemotherapyChemotherapy scheduleOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
DeMichele A, Dueck A, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer C, Nowecki Z, Iwata H, Wolmark N, Parraga K, Rugo H, Steger G, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall K, Lu R, O’Brien P, Fesl C, Mayer E, Gnant M. Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]). Breast Cancer Research 2025, 27: 12. PMID: 39849600, PMCID: PMC11761723, DOI: 10.1186/s13058-024-01941-3.Peer-Reviewed Original ResearchConceptsLocoregional relapse-free survivalStandard adjuvant endocrine therapyYears of palbociclibAdjuvant endocrine therapyEndocrine therapyOverall survivalStage IIAPALLAS trialBreast cancerFollow-upBreast cancer-free survivalReducing breast cancer recurrenceStage IIA patientsHigher stage diseaseHormone-receptor-positiveRelapse-free survivalStage IIA diseaseYears of follow-upCancer-free survivalMedian follow-upPhase III trialsEarly breast cancerBreast cancer recurrenceBreast Cancer Study GroupNegative breast cancer
2024
Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience
Patel R, Jin C, Jaber D, Casasanta N, Jain M, Fu W, Wu C, Moshier E, Tiersten A. Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience. Clinical Breast Cancer 2024, 25: 283-290. PMID: 39837695, DOI: 10.1016/j.clbc.2024.12.020.Peer-Reviewed Original ResearchConceptsLobular carcinoma in situDuctal carcinoma in situLow dose tamoxifenCarcinoma in situAtypical hyperplasiaBreast cancer preventionLog-binomial modelsRetrospective chart review of womenPoison regression modelsChart review of womenIncidence rate of AEFrequency of adverse eventsReview of womenCompare adverse event ratesRetrospective chart reviewHigh-risk lesionsAdverse event ratesCancer preventionIncidence rateAromatase inhibitorsAtypical lesionsAdverse eventsRegression modelsDisease characteristicsHyperplasiaAssociation Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States
Reddy K, Jarrell K, Berkowitz C, Hulse S, Elmore L, Fishman R, Greenup R, Mateo A, Rothman J, Sataloff D, Tchou J, Zafar S, Fayanju O. Association Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States. Annals Of Surgical Oncology 2024, 32: 2534-2544. PMID: 39694997, PMCID: PMC11882630, DOI: 10.1245/s10434-024-16586-x.Peer-Reviewed Original ResearchConceptsBreast cancer careCancer careEmergency departmentBreast cancerWeighted proportion of patientsMedical Expenditure Panel SurveyPrescription medication expendituresOffice-based encountersProportion of patientsOffice-based visitsOut-of-pocketAssociated with increased resource utilizationChi-square testRao-ScottFinancial barriersHealthcare expendituresInpatient expendituresMedical careHealthcare spendingBreast cancer patientsMedical expendituresCareUnited StatesResource utilizationPanel SurveySleep Deficiency A Symptoms Perspective: Exemplars from Chronic Heart Failure, Inflammatory Bowel Disease, and Breast Cancer
Redeker N, Conley S, Hwang Y. Sleep Deficiency A Symptoms Perspective: Exemplars from Chronic Heart Failure, Inflammatory Bowel Disease, and Breast Cancer. Sleep Medicine Clinics 2024, 19: 537-548. PMID: 39455175, DOI: 10.1016/j.jsmc.2024.07.003.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsChronic DiseaseFatigueFemaleHeart FailureHumansInflammatory Bowel DiseasesSleep Wake DisordersConceptsExcessive daytime sleepinessChronic heart failureInflammatory bowel diseaseBreast cancerHeart failureBowel diseaseContributions of sleep deficiencySleep disordersSleep deficiencyPrevalence of fatigueDaytime sleepinessDaytime symptomsChronic conditionsBreastCancerDeficiencySymptomsDiseaseSleepDisordersFatigueIdentification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature Communications 2024, 15: 10402. PMID: 39613746, PMCID: PMC11607438, DOI: 10.1038/s41467-024-54621-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase III as TopicFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2TrastuzumabTumor MicroenvironmentConceptsHER2-positive breast cancerMolecular subtypesBreast cancerRate of pathological complete responseSensitive to HER2-targeted therapiesClinical trialsRisk of distant recurrenceBreast cancer molecular subtypesPathological complete responseHER2-targeted therapyCancer molecular subtypesPotential clinical implicationsNeoALTTO trialDistant recurrenceComplete responseAdjuvant trastuzumabPrognostic/predictive valueHeterogeneous biologySurvival outcomesI-SPY2Clinical outcomesMicroenvironment featuresGene expression profilesExternal cohortTumorAmerican College of Surgeons Operative Standards and Breast Cancer Outcomes
Taylor C, Wang T, Baskin A, Sinco B, Hughes T, Boffa D, Boughey J, Dossett L. American College of Surgeons Operative Standards and Breast Cancer Outcomes. JAMA Network Open 2024, 7: e2446345. PMID: 39565622, PMCID: PMC11579798, DOI: 10.1001/jamanetworkopen.2024.46345.Peer-Reviewed Original ResearchConceptsAmerican College of SurgeonsSentinel lymph node biopsyAxillary lymph node dissectionInvasive breast cancerLymph node yieldNodal positivity rateShort-term oncological outcomesBreast cancerCohort studyNational Cancer DatabaseNodal yieldAmerican CollegeFacility-level variationNodal upstaging rateCohort study of womenUpstaging rateOncological outcomesNode yieldHospital registry dataPotential associationStudy of womenAxillary surgeryCollege of SurgeonsMain OutcomesPoisson regressionScalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience
Lee V, Loh J, Hui F, Sundar R, Tan B, Lee M, Lin H, Ong L, Visvanadan N, Ow S, Wong A, Chan G, Lim S, Lim Y, Tan D, Ang Y, Choo J, Lee M, Ngoi N, Lee S, Paxman R, Parker A, Lee Y, Lim J. Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience. Supportive Care In Cancer 2024, 32: 762. PMID: 39482416, DOI: 10.1007/s00520-024-08940-2.Peer-Reviewed Original ResearchConceptsHair preservationGynaecological cancerChemotherapy-induced alopeciaScalp cooling therapyHair regrowthCooling therapyTaxane-based chemotherapyCycles of chemotherapyAnthracycline based chemotherapyResultsEighty-three patientsGrade (GComfort scoresWeekly paclitaxelPaclitaxel regimenBased chemotherapyComfort levelChemotherapy cyclesTerminology criteriaAdverse eventsHistorical controlsInstitutional experienceChemotherapyChemotherapy-induced hair lossDrug infusionResultsEighty-threeAdvances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55: 6. PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsFemaleHumansMolecular Targeted TherapyMutationPrecision MedicineConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutationsClass Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, Aharon S, Kosenko A, Zundelevich A, Berger R, Ishay-Ronen D. Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. Cells 2024, 13: 1506. PMID: 39273076, PMCID: PMC11394433, DOI: 10.3390/cells13171506.Peer-Reviewed Original ResearchConceptsMEK inhibitorsBreast cancer cellsEpithelial-to-mesenchymal transitionCancer cellsPPARg agonistsDrug resistanceTherapeutic approachesTriple-negative breast cancerMurine breast cancer cellsAggressive breast cancer subtypeDevelopment of drug resistanceCancer cell plasticityBreast cancer subtypesCombination of pioglitazoneOvercome drug resistanceDedifferentiated cancer cellsBreast cancer progressionCancer cell differentiationCytoskeleton rearrangementLipid droplet accumulationCell trans-differentiationBreast cancerCancer subtypesCell plasticityTherapeutic strategiesBreast Cancers Detected during a Decade of Screening with Digital Breast Tomosynthesis: Comparison with Digital Mammography.
Philpotts L, Grewal J, Horvath L, Giwerc M, Staib L, Etesami M. Breast Cancers Detected during a Decade of Screening with Digital Breast Tomosynthesis: Comparison with Digital Mammography. Radiology 2024, 312: e232841. PMID: 39287520, DOI: 10.1148/radiol.232841.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreastBreast NeoplasmsEarly Detection of CancerFemaleHumansMammographyMiddle AgedRetrospective StudiesConceptsDigital breast tomosynthesisBreast cancerDigital mammographyAdvanced cancerHuman epidermal growth factor 2-positiveOverdiagnosis of breast cancerProportion of advanced cancersBreast cancer detection rateEffectiveness of digital breast tomosynthesisRate of advanced cancerDuctal carcinoma in situInterval cancer rateTwo-dimensional digital mammographyInvasive cancer sizeTriple-negative tumorsCancer detection rateCarcinoma in situBreast tomosynthesisFalse-negative findingsIncreased cancer detectionIncident screensIncident roundsAxillary nodesDM screeningInvasive cancerPredicting spatially resolved gene expression via tissue morphology using adaptive spatial GNNs
Song T, Cosatto E, Wang G, Kuang R, Gerstein M, Min M, Warrell J. Predicting spatially resolved gene expression via tissue morphology using adaptive spatial GNNs. Bioinformatics 2024, 40: ii111-ii119. PMID: 39230702, PMCID: PMC11373608, DOI: 10.1093/bioinformatics/btae383.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleGene Expression ProfilingHumansNeural Networks, ComputerTranscriptomeConceptsGene expressionSpatial gene expressionSpatial transcriptomics technologiesTissue histology imagesExpressed genesGene activationTranscriptomic technologiesMolecular underpinningsGraph neural networksState-of-the-artSpatial expressionGenesTissue architectureExpressionHistological imagesNeural network
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply